Lantheus Holdings, Inc. (LNTH): Shareholders' Equity
$1.09B
As of 2025-12-31
$1.31B
As of 2026-06-30
+34.6%
3-year compound annual growth
+16.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.09B | +0.2% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $1.09B | +33.4% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $815.89M | +82.5% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $447.15M | -3.7% | 2025-02-26, Balance as of period end |
| 2021-12-31 | $464.44M | -9.7% | 2024-02-22, Balance as of period end |
| 2020-12-31 | $514.21M | +348.7% | 2023-02-23, Balance as of period end |
| 2019-12-31 | $114.60M | +61.4% | 2022-02-24, Balance as of period end |
| 2018-12-31 | $71.00M | +204.8% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $23.29M | n/m | 2020-02-25, Balance as of period end |
| 2016-12-31 | -$106.52M | n/m | 2019-02-20, Balance as of period end |
| 2015-12-31 | -$185.29M | n/m | 2018-02-26, Balance as of period end |
| 2014-12-31 | -$239.27M | n/m | 2017-02-23, Balance as of period end |
| 2013-12-31 | -$235.52M | n/a | 2016-03-02, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $1.09B | +0.2% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $1.92B | -35.7% |
| Neogen Corp (NEOG) | 2026-05-31 | $2.09B | +1.0% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $368.00M | -47.5% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $1.61B | +0.6% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $671.39M | -23.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $68.78M | -16.5% |
| Immucell Corp (ICCC) | 2025-12-31 | $27.06M | -1.7% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | -$6.93M | n/m |
Compare LNTH, QDEL, NEOG, MYGN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗